XML 58 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration, License, and Other Agreements - Amounts Recognized in Statement of Operations with Roche (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Disaggregation of Revenue [Line Items]        
Revenues $ 3,452.8 $ 2,294.0 $ 11,120.0 $ 6,074.2
Casirivimab and imdevimab | Roche Collaboration Agreement | Collaboration revenue        
Disaggregation of Revenue [Line Items]        
Revenues 127.1 0.0 361.8 0.0
Casirivimab and imdevimab | Roche Collaboration Agreement | Research and development expense        
Disaggregation of Revenue [Line Items]        
Reduction of Research and development expense $ 10.5 $ 9.5 $ 138.3 $ 9.5